Q1 2026 Dexcom Inc Earnings Call Transcript
Key Points
- DexCom Inc (DXCM) reported a 15% increase in first-quarter revenue compared to the same period in 2025, driven by strong demand for its CGM products globally.
- The company successfully launched the DexCom G7 15 Day system, which has been well-received due to its improved sensor algorithm and longer wear time.
- DexCom Inc (DXCM) achieved significant share gains in the type 2 diabetes market, particularly among non-insulin users, supported by expanded coverage and product momentum.
- The company reported a gross profit margin of 63.5%, up from 57.5% in the first quarter of 2025, reflecting strong operational execution and manufacturing efficiencies.
- DexCom Inc (DXCM) closed the quarter with approximately $2.4 billion in cash and cash equivalents, highlighting its strong financial position and significant free cash flow generation.
- The US market for CGM products is experiencing slower growth, with no major coverage expansions or new indications reported.
- DexCom Inc (DXCM) faces potential risks from geopolitical uncertainties, including fuel prices and shipping routes, which could impact gross margin guidance.
- The company has not achieved a record number of new patient starts in the US for four consecutive quarters, raising concerns about growth momentum.
- There is uncertainty regarding the timing of CMS coverage for the type 2 non-insulin population, which is seen as a key driver for future growth.
- DexCom Inc (DXCM) faces competitive pressures in the CGM market, with the need to continually innovate and expand coverage to maintain its market position.
Ladies and gentlemen, welcome to the Dexcom first-quarter 2026 earnings release conference call. My name is Abby, and I will be your operator for today's call. (Operator Instructions) As a reminder, the conference is being recorded.
I will now turn the call over to Sean Christensen, Senior Vice President of Finance and Investor Relations. Mr. Christensen, you may begin.
Thank you, operator, and welcome to Dexcom's first-quarter 2026 earnings call. Our agenda begins with Jake Leach, Dexcom's President and CEO, who will summarize our recent highlights and ongoing strategic initiatives, followed by a financial review and outlook from Jereme Sylvain, our Chief Financial Officer.
Following our prepared remarks, we will open the call up for your questions. (Operator Instructions) Please note that there are also slides available related to our first-quarter 2026 performance on the Dexcom Investor Relations website on the Events and Presentations page.
With that,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
